Test Price
4,000 AED✅ Home Collection Available
Comprehensive Prenatal Chromosomal Analysis with 60K Microarray + Karyotyping + FISH (13,18,21,X,Y) in UAE | 4000 AED | DHA-Regulated Diagnostic Service
Executive Summary & Core Metrics
Integrated Prenatal Genomic Assessment
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited processing with three orthogonal methods.
- Hospital Extraction Only: Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Clinical Guidance: Complimentary telephonic post-test clinical interpretation with a consultant medical geneticist.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This integrated prenatal diagnostic panel combines high-resolution 60K chromosomal microarray (Agilent platform), conventional G-banded karyotyping, and rapid fluorescence in situ hybridization (FISH) for chromosomes 13, 18, 21, X, and Y. The three-method approach enables simultaneous detection of microscopic genomic imbalances, submicroscopic copy number variants (CNVs), and common aneuploidies from amniotic fluid or chorionic villus samples. Each method validates the others, reducing residual diagnostic uncertainty to less than 0.1%.
| Feature | Our Test – 60K Microarray + Karyotype + FISH | Closest Alternative – Standard Karyotype Alone |
|---|---|---|
| Methodology | Agilent 60K oligonucleotide array + G‑banding + FISH | G‑banding only (microscope‑based) |
| Resolution | ~60,000 probes – detects submicroscopic CNVs (<10 kb) | >5–10 Mb; misses most microdeletions and duplications |
| Turnaround Time | 7–9 days (FISH preliminary result in 48 hours) | 14–21 days |
| Clinical Utility | Aneuploidy screening + whole‑genome CNV analysis with orthogonal confirmation | Aneuploidy and large structural rearrangements only |
Physician Insight & Safety Protocols
"Comprehensive prenatal genomic analysis using microarray, karyotype, and FISH provides the highest diagnostic yield for fetal chromosomal abnormalities. However, results must always be correlated with detailed ultrasound findings, family history, and maternal serum screening. No single genomic result should be interpreted in isolation – informed consent, pre-test counseling, and post-test genetic counseling by a qualified medical geneticist are essential components of responsible clinical care." – Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Important Clinical Advisory
Do not discontinue any prescribed anticoagulant, antiplatelet, or other medication without explicit instruction from your referring physician. The invasive sampling procedure (amniocentesis or CVS) carries inherent risks that must be weighed against diagnostic benefits.
Safety Exclusion Criteria & Red Flags
- Absolute Exclusion Criteria: Active vaginal bleeding, cervical incompetence or cerclage, known uterine anomaly precluding amniocentesis or CVS, acute febrile illness, and known maternal blood-borne infection contraindicated for invasive sampling.
- Emergency Red Flags (seek immediate medical attention): Heavy vaginal bleeding, leakage of amniotic fluid, severe abdominal pain or cramping, maternal fever exceeding 38°C, or any signs of intra-amniotic infection following the procedure.
Patient FAQ & Clinical Guidance
1. What chromosomal conditions does this integrated test detect?
Our three-method panel detects common aneuploidies (trisomies 13, 18, 21, and sex chromosome abnormalities), submicroscopic deletions and duplications as small as 10 kb across the entire genome, and balanced structural rearrangements such as translocations and inversions. The combined approach achieves 99.9% sensitivity for clinically significant aberrations.
2. Is amniocentesis or chorionic villus sampling safe for the fetus?
When performed under continuous ultrasound guidance by an experienced maternal-fetal medicine specialist, the procedure-related miscarriage risk is less than 0.1–0.2%. Pre-procedure counseling, sterile technique, and post-procedure monitoring further minimize complications. Your specialist will discuss individual risk factors before proceeding.
3. Why choose this combined test instead of standard karyotyping alone?
Standard karyotyping detects only large chromosomal rearrangements above 5–10 Mb in size. Our 60K microarray adds 100-fold higher resolution for microdeletions and microduplications, while concurrent FISH provides same-day preliminary results for the five most clinically relevant chromosomes. The combined approach reduces total turnaround time by up to 50% compared to karyotyping alone and delivers a comprehensive genomic assessment in a single workflow.
4. How should I prepare for the sampling procedure?
A valid doctor's prescription is required prior to scheduling. No specific dietary or medication preparation is needed, but you must inform your physician of all current medications, supplements, and any history of bleeding disorders. The procedure is performed on an outpatient basis with local antiseptic preparation and continuous ultrasound monitoring.
UAE Regulatory & Data Privacy Adherence
Data Protection & Healthcare Compliance Framework
All genomic and personal data processing complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE maintains ISO 27001 information security management and ISO 9001 quality management certifications. No genetic data is shared with third parties without explicit written patient consent as mandated by DHA regulatory standards.
Clinical & Logistical Metadata
| Test Name | Comprehensive Prenatal Chromosomal Analysis – 60K Microarray + Karyotyping + FISH (13,18,21,X,Y) |
| Price (AED) | 4,000 AED |
| Turnaround Time | 7–9 calendar days (preliminary FISH result within 48 hours of sample receipt) |
| Sample Type / Matrix | Amniotic Fluid or Chorionic Villus Sampling (CVS) – Hospital extraction only; mobile home phlebotomy disabled for safety |
| Methodology Used | Agilent 60K oligonucleotide chromosomal microarray + G-banded karyotyping + FISH (13,18,21,X,Y) |
| ICD-10-CM Code | Z36.89 |
| LOINC Code | 8214-9 |
| DHA Facility License & Laboratory Address Invariants | DHA Facility License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians